pharmaceuticals
pharmaceuticals Articles
Biotech company Can-Fite announced development of its drug candidate CF102, which is currently in phase 2 trials for liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis.
Published:
Last Updated:
Here are 10 stocks that could outperform the index funds from now to early February.
Published:
Last Updated:
24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the past week.
Published:
Last Updated:
Axsome Therapeutics entered the market on Thursday morning at a price below the previously announced expected pricing range.
Published:
Last Updated:
Celladon and Eiger BioPharmaceuticals have announced that they have entered into a definitive merger agreement.
Published:
Last Updated:
Turing Pharmaceuticals CEO Martin Shkreli took a major stake in this small biopharma company KaloBios Pharmaceuticals over the course of this week.
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
Ocera Therapeutics broke out in Tuesday's trading session following positive results from a clinical study.
Published:
Last Updated:
Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
Published:
Last Updated:
Clovis Oncology was leading the bears in Monday’s trading session on news that its lung cancer drug may be delayed.
Published:
Last Updated:
Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early clinical stages.
Published:
Last Updated:
The biotech companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week.
Published:
Last Updated:
Alcobra has announced the pricing of its underwritten secondary offering for more than 6 million shares.
Published:
Last Updated:
Hutchison China MediTech has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
In a fresh report, Janney Capital Markets has said that bad news for Horizon Pharma is creating a buying opportunity in DepoMed.
Published:
Last Updated: